Alternatives to Leqvio If You Can't Fill Your Prescription

Leqvio (inclisiran) is an effective twice-yearly cholesterol injection, but it's not always accessible. Prior authorization denials, clinic availability, and insurance hurdles can delay or block access. If you're in that situation, the good news is that there are several proven alternatives that can also significantly lower your LDL cholesterol.

How Does Leqvio Work (and What Makes a Good Alternative)?

Leqvio is a small interfering RNA (siRNA) that targets PCSK9 messenger RNA in the liver, preventing the production of the PCSK9 protein. PCSK9 normally degrades LDL receptors; blocking it means more receptors are available to clear LDL-C from your blood. In clinical trials, Leqvio reduced LDL-C by about 50% on top of statin therapy.

A good alternative will achieve similar LDL-lowering outcomes, even if through a different mechanism or dosing schedule.

Alternative 1: Repatha (Evolocumab) — Monthly PCSK9 Injection

Repatha (evolocumab) is a monoclonal antibody that blocks the PCSK9 protein after it's made (instead of preventing it from being made, like Leqvio). It lowers LDL-C by approximately 60% and has demonstrated a reduction in major adverse cardiovascular events (heart attack, stroke) in the landmark FOURIER trial.

• Dosing: 140 mg every 2 weeks or 420 mg monthly — self-injected at home
• Key advantage: Self-administered; doesn't require a clinic visit; strong CV outcomes data
• Key consideration: More frequent dosing (every 2–4 weeks vs. twice yearly for Leqvio); requires refrigeration

Alternative 2: Praluent (Alirocumab) — Biweekly PCSK9 Injection

Praluent (alirocumab) is another PCSK9 monoclonal antibody, similar to Repatha. It reduces LDL-C by approximately 60% and was shown to reduce cardiovascular events in the ODYSSEY OUTCOMES trial, particularly in patients with recent acute coronary syndrome.

• Dosing: 75 mg or 150 mg every 2 weeks — self-injected at home
• Key advantage: Strong outcomes data; self-administered at home; lower upfront cost than Leqvio
• Key consideration: Requires refrigeration; more frequent injections

Alternative 3: High-Intensity Statins (Atorvastatin, Rosuvastatin)

Statins remain the cornerstone of LDL-lowering therapy. High-intensity statins like atorvastatin 40–80 mg and rosuvastatin 20–40 mg can reduce LDL-C by 50% or more. They're taken daily as pills, widely covered by insurance, and available in generic form for as little as $4–$15/month.

Leqvio is usually considered when statins alone aren't enough, or when a patient can't tolerate statins. If your LDL-C goal hasn't been reached on maximum-dose statins, adding Leqvio (or one of these other options) may be the next step.

Alternative 4: Ezetimibe (Zetia) — Daily Pill

Ezetimibe (sold as Zetia) blocks cholesterol absorption in the intestines. It typically reduces LDL-C by about 20% on top of statin therapy. It's available in generic form, inexpensive (often under $20/month with a coupon), and well-tolerated. Guidelines generally recommend adding ezetimibe before escalating to PCSK9 inhibitors.

Alternative 5: Nexletol (Bempedoic Acid) or Nexlizet — Oral Options for Statin-Intolerant Patients

Bempedoic acid (Nexletol) and the combination pill bempedoic acid/ezetimibe (Nexlizet) are oral options that work via a different pathway than statins. They're particularly useful for patients who can't tolerate statins. Bempedoic acid reduces LDL-C by approximately 18–28% as monotherapy and has shown a reduction in cardiovascular events in the CLEAR Outcomes trial.

How Do These Alternatives Compare to Leqvio?

LDL-C Reduction: Repatha and Praluent match or slightly exceed Leqvio (~60% vs ~50%). Statins can also reach 50%+ at high intensity. Ezetimibe adds ~20%. Bempedoic acid adds ~18–28%.

Convenience: Leqvio wins on dosing frequency (twice yearly). Repatha/Praluent are every 2–4 weeks. Statins and ezetimibe are daily pills.

CV Outcomes Data: Repatha and Praluent have published CV outcomes trials. Leqvio's cardiovascular outcomes trial (ORION-4) is ongoing. Statins have the strongest and longest CV outcomes evidence.

Cost: Generic statins and ezetimibe are by far the least expensive. Leqvio, Repatha, and Praluent are all high-cost specialty drugs, though insurance coverage and patient assistance programs can reduce out-of-pocket costs significantly.

What Should You Do Next?

Talk to your cardiologist or lipid specialist about which alternative is right for your specific situation. If you're still trying to access Leqvio, medfinder can call providers on your behalf to find which ones have it in stock and can schedule your injection promptly.

Read our complete guide: How to Find Leqvio In Stock Near You.